Alpha Teknova, Inc.
TKNO · XNASCIK 1850902fmd_031XN5D2R7AK0Y8VSZAMYB0WQGManufacturing · In Vitro & In Vivo Diagnostic SubstancesTemplate: Standard
Coverage: Jan 01, 2020 to Sep 30, 2026, 26 periods
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Total revenues | 31 | 37 | 41 | 37 | 38 | 41 |
| Cost of revenue | 14 | 19 | 24 | 26 | 31 | 27 |
| Net interest income | 0 | (1) | 0 | (1) | (1) | (1) |
| Gross profit | 18 | 18 | 17 | 10 | 7 | 13 |
| Realized investment gains (losses) | – | 0 | – | – | – | – |
| Research and development | 2 | 4 | 8 | 6 | 3 | 2 |
| Selling, general and administrative | 10 | 24 | 37 | 35 | 29 | 27 |
| Total operating expenses | 13 | 30 | 67 | 46 | 33 | 30 |
| Operating income | 5 | (12) | (50) | (36) | (26) | (17) |
| Other non-operating income (expense) | 0 | (1) | 0 | (2) | (1) | (0) |
| Income before taxes | 5 | (13) | (49) | (37) | (27) | (17) |
| Income tax expense | 1 | (3) | (2) | (0) | (0) | 0 |
| Net income from continuing operations | 4 | (10) | (47) | (37) | (27) | (17) |
| Net income | 4 | (10) | (47) | (37) | (27) | (17) |
| Net income to common shareholders | 1 | (10) | – | – | – | – |